419 POSTER A phase I safety and pharmacokinetic (PK) study of 3 and 6 hours (h) intravenously administered belinostat (PXD101) plus carboplatin (C) and paclitaxel (P) in patients (pts) with advanced solid tumours
EJC SUPPLEMENTS（2008）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要